Pharmacological repression of PPARγ promotes osteogenesis.
Pharmacological repression of PPARγ promotes osteogenesis.
复制标题
DOI:
10.1038/ncomms8443
复制
发表时间:
2015-06-12
影响因子:
16.6
通讯作者:
Griffin, Patrick R.
中科院分区:
文献类型:
--
作者:
Marciano, David P.;Kuruvilla, Dana S.;Boregowda, Siddaraju V.;Asteian, Alice;Hughes, Travis S.;Garcia-Ordonez, Ruben;Corzo, Cesar A.;Khan, Tanya M.;Novick, Scott J.;Park, HaJeung;Kojetin, Douglas J.;Phinney, Donald G.;Bruning, John B.;Kamenecka, Theodore M.;Griffin, Patrick R.
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently we reported the development of PPARγ antagonist SR1664, designed to block the obesity induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPARγ, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow derived mesenchymal stem cells (MSCs) with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand mediated PPARγ repression, and suggest a therapeutic approach to promote bone formation.
登录
查看更多内容
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
82.9
作者:
通讯作者:
--
影响因子:
16
作者:
Rocchi, S;Picard, F;Auwerx, J
通讯作者:
Auwerx, J
影响因子:
7.7
作者:
Carmona, Maria Carmen;Louche, Katie;Penicaud, Luc
通讯作者:
Penicaud, Luc
影响因子:
16.6
作者:
Hughes, Travis S.;Giri, Pankaj Kumar;de Vera, Ian Mitchelle S.;Marciano, David P.;Kuruvilla, Dana S.;Shin, Youseung;Blayo, Anne-Laure;Kamenecka, Theodore M.;Burris, Thomas P.;Griffin, Patrick R.;Kojetin, Douglas J.
通讯作者:
Kojetin, Douglas J.